Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience

Table 1

Demographic and diagnostic information of all included patients.

Patient number	Age	Sex	Affected eye	Associated disease	Location of uveitis	AC infl (SUN)	Vitr infl (SUN)	Macular edema^1
1	36	M	OD	Psoriatic arthritis	Anterior	Active	Inactive	No
2	20	F	OU	Sarcoidosis	Panuveitis	Active	Inactive	Yes
3	27	M	OU	Sarcoidosis	Intermediate	Inactive	Active	No
4	31	F	OD	Psoriatic arthritis	Anterior	Active	Inactive	No
5	34	M	OD	JIA	Anterior	Active	Inactive	No
6	37	M	OS	Axial SpA	Anterior	Active	Active	Yes
7	22	M	OU	VKH	Panuveitis	Active	Active	Yes
8	32	M	OU	Axial SpA	Anterior	Active	Inactive	Yes
9	21	F	OU	JIA	Anterior	Active	Inactive	Yes
10	23	F	OU	JIA	Anterior	Active	Inactive	Yes
11	24	F	OU	JIA	Anterior	Active	Inactive	No
12	38	M	OU	Behçet	Panuveitis	Active	Active	Yes
13	30	M	OU	Behçet	Panuveitis	Inactive	Active	Yes

M: male; F: female; OD: right eye; OS: left eye; OU: both eyes; JIA: Juvenile idiopathic arthritis; VKH: Vogt-Koyanagi-Harada syndrome; Ac infl (SUN): anterior chamber inflammation base on Standardization of uveitis nomenclature criteria. (Ref.) Vitr infl (SUN): vitreous inflammation base on Standardization of uveitis nomenclature criteria. (Ref.).
¹Macular edema was defined as central macular thickness >300 μ and/or presence of intraretinal cysts in optical coherence tomography (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA, USA). The 1 mm central retinal thickness was evaluated using the macular cube strategy 512×128.